Caris Life SciencesCAI.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Richly Valued” zone.
As of Oct 16, 2026, Caris Life Sciences (CAI.O) trades at a P/E of 82.00x, P/B of 14.60x, P/S of 8.73x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 94th percentile over the trailing 10Y window (vs. 94th percentile over 3Y); P/B sits at the 63rd percentile over the trailing 10Y window (vs. 63rd percentile over 3Y); P/S sits at the 56th percentile over the trailing 10Y window (vs. 56th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 86th percentile within its industry and the 92nd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%, ranking at the 43rd percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 30.9 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Caris Life Sciences operates in the Services sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: CAI · CAI
Want the full picture on whether Caris Life Sciences (CAI.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 82.00 | ||||||
| P/B (MRQ) | 14.60 | ||||||
| P/S (TTM) | 8.73 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.00% |